These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3995687)

  • 21. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.
    Kellokumpu-Lehtinen P; Nordman E
    J Biol Response Mod; 1990 Aug; 9(4):439-44. PubMed ID: 2395008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adjuvant chemotherapy with vinblastine, adriamycin and UFT (VAU) for renal cell carcinoma].
    Masuda F; Nakada J; Kondo I; Furuta N
    Gan To Kagaku Ryoho; 1991 Sep; 18(12):2143-6. PubMed ID: 1888185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
    Mickisch GH; Noordzij MA; vd Gaast A; Gebreamlack P; Köhrmann KU; Mogler-Drautz E; Kupper H; Schröder FH
    J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R11-6. PubMed ID: 8698736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chemotherapy of metastatic renal cell carcinoma with cis-diamminedichloroplatinum and other drugs].
    Okumura S; Nishimura T; Yoshida K; Ohhara M; Hasegawa J; Hirasawa S; Hara M; Kawamura N; Kanamori S; Akimoto M
    Hinyokika Kiyo; 1984 Sep; 30(9):1167-71. PubMed ID: 6084420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined interferon and vinblastine treatment of advanced melanoma and renal cell cancer.
    Kellokumpu-Lehtinen P; Nordman E
    Cancer Detect Prev; 1988; 12(1-6):523-9. PubMed ID: 3180144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of five-day continuous infusion of vinblastine in patients with metastatic renal-cell carcinoma.
    Crivellari D; Tumolo S; Frustaci S; Galligioni E; Figoli F; Lo Re G; Veronesi A; Monfardini S
    Am J Clin Oncol; 1987 Jun; 10(3):231-3. PubMed ID: 3591744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
    Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
    Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survey of chemotherapy of metastatic renal cancer.
    Kühböck J
    Semin Surg Oncol; 1988; 4(2):87-90. PubMed ID: 3293155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Circumvention of the multidrug-resistance in renal cancer by bisbenzylisoquinoline].
    Kakehi Y; Hashimura T; Yoshida O; Segawa T; Kanematsu A
    Hinyokika Kiyo; 1993 Dec; 39(12):1227-32. PubMed ID: 8285174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
    Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
    Tsavaris N; Skarlos D; Bacoyiannis C; Aravantinos G; Kosmas C; Retalis G; Panopoulos C; Vadiaka M; Dimitrakopoulos A; Kostantinidis K; Mitropoulos D; Bougas D; Pantazopoulos D; Kosmidis P
    J Interferon Cytokine Res; 2000 Aug; 20(8):685-90. PubMed ID: 10954911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer.
    Hahn RG; Temkin NR; Savlov ED; Perlia C; Wampler GL; Horton J; Marsh J; Carbone PP
    Cancer Treat Rep; 1978 Jul; 62(7):1093-5. PubMed ID: 356971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study.
    Murphy BR; Rynard SM; Pennington KL; Grosh W; Loehrer PJ
    Am J Clin Oncol; 1994 Feb; 17(1):10-3. PubMed ID: 8311000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant chemotherapy with vinblastine, adriamycin, and UFT for renal-cell carcinoma.
    Masuda F; Nakada J; Kondo I; Furuta N
    Cancer Chemother Pharmacol; 1992; 30(6):477-9. PubMed ID: 1394804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
    Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
    Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
    Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.